Investigating proteins that may reduce lung scarring in pulmonary fibrosis
Microfibril-associated glycoproteins attenuating pulmonary fibrosis
['FUNDING_CAREER'] · WASHINGTON UNIVERSITY · NIH-11051786
This study is looking at a lung disease called idiopathic pulmonary fibrosis (IPF) and is exploring how certain proteins made by cells in the lungs might help control the scarring process, with the hope of finding new treatments to help people with this condition feel better.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11051786 on ClinicalTrials.gov |
What this research studies
This research focuses on idiopathic pulmonary fibrosis (IPF), a serious lung disease characterized by progressive scarring and limited treatment options. The study examines the role of specific proteins, known as microfibril-associated glycoproteins (Magps), which are produced by fibroblasts and may help regulate a key signaling pathway involved in fibrosis. By understanding how these proteins function and their potential to inhibit fibrotic signaling, the research aims to identify new therapeutic strategies that could improve patient outcomes. The approach includes genetic studies in mice to explore the effects of these proteins on lung injury and fibrosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis who are experiencing progressive lung symptoms.
Not a fit: Patients with other forms of lung disease or those who do not have idiopathic pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively reduce lung scarring and improve breathing in patients with pulmonary fibrosis.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in fibrosis, suggesting that this approach could yield beneficial results.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KOENITZER, JEFFREY — WASHINGTON UNIVERSITY
- Study coordinator: KOENITZER, JEFFREY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.